Palvella Therapeutics (PVLA) Cost of Revenue (2013 - 2014)
Palvella Therapeutics (PVLA) posted quarterly Cost of Revenue of $18.0 for Q3 2014, up 50.0% year-over-year from $12.0 in Q3 2013, and up 50.0% quarter-over-quarter from $12.0 in Q3 2013.
Powered by 
Analysis
Palvella Therapeutics (PVLA) Cost of Revenue (2013 - 2014) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Cost of Revenue for 2 consecutive years, with $18.0 the latest figure, recorded in Q3 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |